<?xml version="1.0"?>

<document>
	<title>Evaluation of long term tobramycin therapy in patients with cystic
   fibrosis and advanced pulmonary disease.</title>

	<author>Paporisz-U.</author>
	<author>Posselt-H-G.</author>
	<author>Wonne-R.</author>
	<author>Ristow-W.</author>
	<author>Roser-D.</author>
	<author>Knothe-H.</author>
	<author>Bender-S-W.</author>

	<source>Eur-J-Pediatr. 1979 Apr 3. 130(4). P 259-69.</source>

	<abstract>To nine cystic fibrosis patients with chronic bronchopulmonary
   infection of severely damaged lungs invaded by Pseudomonas
   aeruginosa, eleven courses of prolonged tobramycin treatment (5
   mg/kg/day) for four to 16 weeks were administered. Pulmonary symptoms
   improved and a better quality of life was achieved in all but one
   patient. Objective parameters (chest X-ray, pulmonary function tests)
   changed to a lesser extent. In only one patient was Pseudomonas
   eradicated from the sputum but reappeared after discontinuation of
   therapy. In the rest of the patients Pseudomonas was significantly
   suppressed or replaced by other pathogens. Four patients showed rises
   of antibody titres to Candida and two to Aspergillus fumigatus. No
   nephrotoxic side effects were observed, but vestibular function was
   reversibly impaired in one patient without corresponding clinical
   symptoms. No bacterial resistance to tobramycin was observed during
   therapy.</abstract>

	<majorsubject>ANTIBIOTICS: tu</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: dt</majorsubject>
	<majorsubject>LUNG-DISEASES: dt</majorsubject>
	<majorsubject>TOBRAMYCIN: tu</majorsubject>

	<minorsubject>ADOLESCENCE</minorsubject>
	<minorsubject>ADULT</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>CYSTIC-FIBROSIS: ra</minorsubject>
	<minorsubject>FEMALE</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>LUNG-DISEASES: ra</minorsubject>
	<minorsubject>MALE</minorsubject>
	<minorsubject>PSEUDOMONAS-INFECTIONS: dt</minorsubject>
	<minorsubject>RESPIRATORY-FUNCTION-TESTS</minorsubject>
	<minorsubject>TIME-FACTORS</minorsubject>
	<minorsubject>TOBRAMYCIN: ad, ae</minorsubject>

	<reference>001   BOXERBAUM B           J INFECT DIS SUPPL             124   293 971</reference>
	<reference>002   DOGGETT RG            SOUTH MED J                     61  1347 968</reference>
	<reference>003   DOGGETT RG            J BACTERIOL                     87   427 964</reference>
	<reference>004   DOGGETT RG            SOUTH MED J                     57  1476 964</reference>
	<reference>005   DOGGETT RG            SOUTH MED J                     57  1470 964</reference>
	<reference>006   DOGGETT RG            SOUTH MED J                     61  1346 968</reference>
	<reference>007   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969</reference>
	<reference>008   DOGGETT RG            BACT PROC                       69    87 969</reference>
	<reference>009   DOGGETT RG            INFECT IMMUN                     6   628 972</reference>
	<reference>010   HAWLEY HB             CURR THER RES                   16   414 974</reference>
	<reference>011   HARRISON GM           PAEDIATRICIAN                    1   180 972</reference>
	<reference>012   HOFF GE               SCAND J INFECT DIS               6   333 974</reference>
	<reference>013   HOIBY N               SCAND J RESPIR DIS              58    65 977</reference>
	<reference>014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974</reference>
	<reference>015   HUMPHREY JH           ADV IMMUNOL                     11    75 969</reference>
	<reference>016   MAY JR                CHEMOTHERAPY OF CHRONIC BRONC            968</reference>
	<reference>017   MEARNS MB             ARCH DIS CHILD                  47   902 972</reference>
	<reference>018   WAITZ JA              ANTIMICROB AGENTS CHEMOTHER      2   431 972</reference>


</document>
